A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve memory in mild Alzheimer’s patients
New Zealand’s women beat newly-crowned world sevens series champions Australia 21-14 in the final leg in Toulouse.
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve memory in mild Alzheimer’s patients
New Zealand’s women beat newly-crowned world sevens series champions Australia 21-14 in the final leg in Toulouse.
A phase 1 pilot trial suggests that a novel egg-shell derived peptide may reduce Alzheimer’s biomarkers and improve memory in mild Alzheimer’s patients
New Zealand’s women beat newly-crowned world sevens series champions Australia 21-14 in the final leg in Toulouse.
LEADERS
INVESTMENTS
INNOVATION
PARTNERSHIPS
In-Depth Analysis

In-Depth Analysis
Expert Opinions

Expert Opinions
Funding & IPOs

Funding & IPOs
Clinical Results & Milestones

Clinical Results & Milestones
EDITOR’S PICKS
Leading biopharma firms are harnessing AI-driven collaborations to accelerate drug discovery and deliver transformative healthcare solutions.
The Reporter Newsletter
A new collaboration aims to develop VMX-C001 to treat severe bleeding in patients on anticoagulants, targeting a 2029 launch
A new collaboration aims to develop VMX-C001 to treat severe bleeding in patients on anticoagulants, targeting a 2029 launch
Watch Now
Recent clinical developments offer hope for immunosuppression-free diabetes treatment while raising serious questions about safety in gene therapy for muscular …
Major investment strengthens pharmaceutical supply chain resilience and advances green manufacturing practices in North America.
Recommended Post
Listen Now
Moderna’s mRNA-1345 demonstrates 83% efficacy against RSV in adults 60+, positioning it as a frontrunner in next-gen respiratory vaccines.
Triple-drug combination extending life for women with aggressive HR+/HER2− breast cancer
December 18 brings a milestone for cell therapy in graft-versus-host disease—and a setback for Duchenne muscular dystrophy research, highlighting the regulatory tightrope in advanced therapeutics.
Clinical-stage companies AC Immune and Edgewise Therapeutics shared encouraging updates on their immunotherapy and cardiac medicine programs, signaling important momentum in neurodegenerative and cardiovascular research.
Ready To Explore Industry News?
All articles are free -no payment or registration required.





























